These results suggest that implementing endocrine therapy during the presurgical waiting period may effectively reduce tumor size and Ki67 expression levels and that the PEPI score may serve as a valuable predictor for the prognosis of postmenopausal women with HR+ breast cancer. This evidence concerns the gene MKI67 and breast cancer.